LENSAR, Inc. Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $16.5 million, up 18% year-over-year.

Recurring Revenue: $13.7 million, a 20% increase, representing 83% of total revenue.

Procedure Revenue: $10.2 million, reflecting a 23% year-over-year growth.

Procedure Volume: 58,682 procedures performed, a 13% increase from the previous year.

Adjusted EBITDA: $3.6 million, the strongest performance to date.

GAAP Net Income: $3.5 million, compared to a net loss of $1.8 million in Q2 2025.

Gross Margin: Approximately 59%, benefiting from a $1.1 million tariff refund; without this, gross margin was 52%.

Installed Base: 215 ALLY systems, with a total of 445 systems worldwide, up from 410 a year ago.

2Strategic Updates and Business Highlights

The termination of the proposed merger with Alcon has allowed LENSAR to refocus on independent operations and long-term growth strategies.

Continued strong demand for the ALLY system, with increased market share in the U.S. rising to 24.1%.

The company is expanding its presence in Europe, planning to participate in the ESCRS conference to enhance surgeon education and interest in the ALLY system.

A backlog of 13 ALLY systems provides visibility into future placements.

3Forward Guidance and Outlook

LENSAR expects to see variability in income and EBITDA as operating expenses normalize following strategic investments.

The company is optimistic about sustaining growth in recurring revenue and procedures, which are key drivers for long-term profitability.

Management is focused on increasing the installed base and utilization of ALLY systems, which should enhance recurring revenue streams.

4Bad News, Challenges, or Points of Concern

The third quarter typically sees a decline in cataract surgery procedures due to seasonal factors, which may impact revenue.

The company faces challenges in reestablishing distributor relationships, particularly in international markets, following the merger termination.

There is uncertainty regarding the timing of backlog installations, particularly in the U.S. where some facilities are experiencing construction delays.

5Notable Q&A Insights

Management provided insight into the backlog composition, indicating a mix of U.S. and international placements, with some delays due to facility readiness.

There is a cautious outlook on recurring revenue per procedure, with expectations for modest increases as more U.S. systems are installed.

The pricing strategy for ALLY systems appears stable, with slight fluctuations based on sales to distributors and private equity groups.

Management acknowledged the importance of the upcoming ESCRS conference for rebuilding distributor relationships and expanding market presence in Europe. Overall, LENSAR demonstrated strong financial performance in Q2 2026, with a clear focus on growth and strategic initiatives, despite facing some seasonal and operational challenges.